rPmpD in combination with SLA elicits significant protection against intra-vaginal Ct challenge.
Antibodies induced by immunisation with rPmpD recognise Ct elementary bodies.
SLA is a novel adjuvant class that may be widely used in future preclinical Ct vaccine development.